HD12 for Advanced Stages

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Liposomal doxorubicin; Prednisone; Procarbazine; Vincristine

Criteria

Inclusion Criteria:

• Hodgkin´s lymphoma (histologically proven)

• CS(PS) IIB with one or both of the risk factors:

1. bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)

2. extranodal involvement

• CS(PS) III, IV

• written informaed consent

Exclusion Criteria:

• Leukocytes <3000/microl

• Platelets <100000/microl

• Hodgkin´s Disease as "composite lymphoma"

• Activity index (WHO) < grade 2